| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 122.06 | 43.2% | 33.3% |
| Total Income | 122.06 | 43.2% | 33.3% |
| Expenditure | 46.58 | 16.7% | 29.4% |
| PBT | 68.02 | 79.8% | 291.6% |
| Net Profit | 40.08 | 69.8% | 998.1% |
| OPM | 61.84% | 8.67pp | 33.85pp |
| NPM | 32.84% | 5.15pp | 28.85pp |
| EPS | 0.25 | 66.7% | 1150.0% |
Ironwood Pharmaceuticals Reports Strong Q3 2025 Results; Raises Full Year Guidance
04 May 2026 · 4 May, 7:31 am
Summary
Ironwood Pharmaceuticals reported strong third quarter 2025 results, driven by LINZESS performance. LINZESS U.S. net sales increased by 40% year-over-year to $315 million. GAAP net income was $40 million and adjusted EBITDA was $82 million. The company raised its full-year 2025 financial guidance for LINZESS U.S. net sales to $860 - $890 million, total revenue to $290 - $310 million, and adjusted EBITDA to greater than $135 million. The FDA approved LINZESS for the treatment of IBS-C in patients 7 years and older.
Key Highlights
- 1
LINZESS U.S. net sales reached $315 million in Q3 2025, reflecting a 40% increase year-over-year.
- 2
The company reported GAAP net income of $40 million and adjusted EBITDA of $82 million for Q3 2025.
- 3
Ironwood ended Q3 2025 with $140 million in cash and cash equivalents.
- 4
Full-year 2025 LINZESS U.S. net sales guidance was raised to $860 - $890 million.
- 5
Total revenue guidance for 2025 is now projected to be $290 - $310 million.
- 6
Adjusted EBITDA guidance for full-year 2025 was raised to greater than $135 million.
- 7
The FDA approved LINZESS as the first drug for the treatment of children 7 years and older with irritable bowel syndrome with constipation (IBS-C).
Management Comments
Tom McCourt
LINZESS delivered a strong third-quarter performance, driven by accelerated double-digit prescription demand growth combined with improved net pricing, which prompted us to raise our full-year 2025 financial guidance. Importantly, we expect our strong third-quarter revenue will result in substantial fourth-quarter cash flows, which will strengthen our financial position, enable us to reduce our debt and maintain compliance with debt covenants over the coming quarters. As part of our ongoing commitment to patients, we continue to seek ways to expand the clinical utility of LINZESS. This month, the FDA approved LINZESS for the treatment of IBS-C in patients 7 years of age and older. We also remain focused on advancing the apraglutide program toward a confirmatory Phase 3 trial, with plans to align on a trial design with the FDA later this year. Pending that alignment, we expect to initiate a Phase 3 confirmatory study in the first half of 2026. In addition, we continue to review strategic alternatives to maximize shareholder value and look forward to providing an update on that process as appropriate
Informational and educational content only. Not investment advice.